Analysts Set Artelo Biosciences, Inc. (NASDAQ:ARTL) Target Price at $24.00

Artelo Biosciences, Inc. (NASDAQ:ARTL) has been assigned a consensus rating of “Hold” from the five research firms that are currently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation, one has assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $24.00.

A number of equities analysts recently commented on ARTL shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Artelo Biosciences in a research note on Wednesday, October 8th. D. Boral Capital reaffirmed a “hold” rating on shares of Artelo Biosciences in a report on Monday, September 8th. D Boral Capital cut Artelo Biosciences from a “strong-buy” rating to a “hold” rating in a report on Monday, September 8th. Finally, Wall Street Zen cut Artelo Biosciences to a “strong sell” rating in a report on Saturday, August 9th.

Artelo Biosciences Price Performance

Shares of Artelo Biosciences stock opened at $3.38 on Thursday. The business has a 50-day moving average of $5.90 and a 200-day moving average of $7.80. The company has a market capitalization of $2.37 million, a PE ratio of -0.18 and a beta of 1.41. Artelo Biosciences has a 1-year low of $3.15 and a 1-year high of $28.60.

Artelo Biosciences (NASDAQ:ARTL) last posted its quarterly earnings results on Wednesday, August 13th. The company reported ($5.61) EPS for the quarter, missing analysts’ consensus estimates of ($0.13) by ($5.48). On average, equities analysts expect that Artelo Biosciences will post -2.62 earnings per share for the current fiscal year.

About Artelo Biosciences

Artelo Biosciences, Inc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders.